SMPD1 and metabolic dysfunction-associated steatohepatitis: In line with the reported role of ASMase-induced ceramide generation in mediating hepatocellular apoptosis and fibrosis, ASMase has emerged as a potential new target for treatment for both ASH and NASH [88].